Trial Profile
Multicentre randomized phase II study of neoadjuvant trastuzumab plus docetaxel with and without bevacizumab and trastuzumab plus docetaxel plus non-pegylated liposome-encapsulated doxorubicin (NPLD) with and without bevacizumab in HER2-positive early breast cancer [Multizentrisch randomisierte Phase II Studie für neoadjuvantes Trastuzumab plus Docetaxel plus nicht pegyliertes liposomal verkapseltes Doxorubicincitrat (NPLD) mit und ohne Bevacizumab bei HER2-positivem frühem Mammakarzinom].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary) ; Docetaxel; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 12 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.